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Abstract
Objective: The objective of this selective EBM was to investigate the question, “Does routine
use of medical cannabis (marijuana) decrease the intensity of neuropathic chronic pain in adults?
Study Design: systematic review of 3 English language primary studies, published between
2005 and 2009.
Data Sources: Three Randomized Controlled Trials (RTC’s) published on or after 2005 were
selected based on their relevance to the proposed question via PubMed. All three RTC’s
compared cannabis use vs. placebo for chronic neuropathic pain, with two RTC’s focusing on
HIV neuropathic pain and the third focusing on MS.
Outcome(s) Measured: The outcomes measured in these trials were by how much medical
cannabis decreases the intensity of chronic neuropathic pain. This was accomplished using three
techniques depending on the study: A self-reporting visual analog scale; a Descriptor Differential
Scale (DDS); and an 11-point numerical sliding scale.
Results: Ronald Ellis and co-authors demonstrated that the proportions of subjects with HIV
achieving at least 30% pain relief with cannabis versus placebo were 0.46 (95%CI 0.28, 0.65)
and 0.18 (0.03, 0.32). Abrams and co-authors demonstrated that smoked cannabis reduced daily
pain with HIV by 34% vs 17% with placebo (p= 0.03). Greater than 30% reduction in pain was
reported by 52% in the cannabis group and by 24% in the placebo group (p= 0.04). Rog and coauthors demonstrated that cannabis was superior to placebo in reducing the mean intensity of
pain of MS (CBM mean change -2.7, 95% CI: -3.4 to -2.0, placebo –1.4 95% CI: -2.0 to -0.8,
comparison between groups, p =0.005).
Conclusions: There is a significant benefit to patients with chronic neuropathic pain when using
medical cannabis vs. placebo in HIV and MS. While the risks and benefits to daily use of
medical marijuana needs to be further investigated, medical cannabis can be an effective
alternative to standard treatments in those who can’t tolerate their side effects.
Key Words: Chronic Pain; Cannabis
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INTRODUCTION
For those with lifelong multisystem medical conditions such as HIV or Multiple
Sclerosis, chronic neuropathic pain characterized by nerve and/or tissue damage causing
recurrent pain over a prolonged period of time is a constant debilitating problem. Multiple
sclerosis is a disease which causes the development of primary lesions on different areas of the
brain, leading to downstream CNS neuropathic pain in an unpredictable manner in 17-52% of
patients. The symptoms largely depend on the individual, but they more frequently involve the
peripheral extremities and can including the sensations of burning, aching, prickling, stabbing, or
squeezing.1 Nearly 32% of MS patients confirm the notion that MS is “frequently disabling and
inadequately managed”.1 For HIV, one of the most common HIV-associated sensory neuropathy
found in as many as 30% of patients is chronic neuropathic pain in the form of aching, burning,
or painful numbness.2,3 Hyperalgesia, or an abnormally heightened sense of pain, is common in
the HIV population as well.3
Chronic pain affects more than 50 million patients annually.4 While there is no clear data
depicting just how many visits there were to health institutions annually, when comparing the
cost of chronic pain to other common ailments, there was a significantly higher cost associated
with chronic pain ($635 billion) than the estimated annual costs of heart disease ($309 billion),
cancer ($243 billion), and diabetes ($188 billion). The $635 billion in annual costs include
healthcare expenses, loss of income, and loss of productivity, which makes this one of the
leading costs in our healthcare system today.5
These chronic neuropathic pains can be quite debilitating which prompts the use of
standard treatments such as NSAIDs and opioid medications as well as biofeedback and topical
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remedies. Treatment for HIV-associated sensory neuropathy also includes anticonvulsants such
as lamotrigine and gabapentin, however some patients fail to respond or are unable to handle the
side effects of such treatments.3 This has led researchers to explore alternative forms of medicine
for patients with chronic neuropathic pain.
Of the alternative medicines researched, the use of medical cannabis, or marijuana, has
become an important and controversial center of debate. Cannabis is an illicit recreational drug
that causes users to enter a mild state of euphoria. The most abundant active ingredient in
cannabis, tetrahydrocannabinol(THC), and its synthetic derivatives, produce effective analgesia
in most animal models of pain. The antinociceptive effects of THC are mediated through
cannabinoid receptors(CB1, CB2) in the central and peripheral nervous systems, which in turn
interact with noradrenergic and k-opioid systems in the spinal cord to modulate the perception of
painful stimuli. The endogenous ligand of CB1, anandamide, itself is an effective antinociceptive
agent.2
There is a huge stigma associated with cannabis due to it not only being an illegal
substance, but also due to it being in the DEA scheduling category 1; along with LSD, peyote,
and ecstasy. Recently there has been a major movement to decriminalize cannabis for medicinal
use due to its analgesic and euphoric properties. Since 1996, 23 states have legalized medicinal
marijuana, indicating that this will increasingly become more common within the healthcare
field: directly impacting physician assistants and their colleagues.
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OBJECTIVE:
The objective of this selective EBM was to investigate the question, “Does routine use of
medical cannabis (marijuana) decrease the intensity of neuropathic chronic pain in adults?
METHODS:
Research for this review was performed using PubMed using keywords Chronic Pain;
and Cannabis. Articles were selected based on their relevance to the proposed question and
whether they were patient oriented outcomes (POEMS). All articles were Randomized
Controlled Trials (RTC’s), published scholarly peer reviewed articles, and were published in
English between 2005 and 2007.
Three studies were included in this review: Randomized, controlled trial of cannabisbased medicine in the central pain in multiple sclerosis by Rog et al1; Smoked Medical Cannabis
for Neuropathic Pain HIV by Ellis et al2; and Cannabis in Painful HIV-Associated Sensory
Neuropathy: A randomized Placebo-Controlled Trial by Abrams et al3. Criteria used for selection
of these studies included chronic neuropathic pain in male and female adults due to MS or HIV
and intervention using cannabis with a comparison to placebo to decrease the intensity of chronic
neuropathic pain. Inclusional criteria varied slightly by trial but typically included adults with
chronic pain, prior lifetime cannabis used, and a negative toxicology screening prior to start of
trial. Exclusional criteria also varied slightly by trial but typically included a negative history of
substance abuse, psychiatric disorders, or unstable disease. Each article used a different style of
measurement to determine clinical significance (visual analog scale, descriptor differential scale,
and an 11-point numerical scale) between intervention and control and included p-values, RRR,
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ARR, and NNT in their statistical analysis. The demographics and characteristics of the included
studies are displayed in Table 1.

Table 1 - Demographics & Characteristics of included studies
Study

Rog1
(2005)

Ellis2
(2009)

Abrams5
(2007)

Type

RCT

RCT

RCT

#Pts

64

26

50

Age
(yrs)

Mean:
49.2 y/o

Mean:
49.1 y/o

Mean:
48.5 y/o

Inclusion
Criteria
1. Adult
patients with
central
neuropathic
pain
syndrome
due to
multiple
sclerosis for
at least 6
months
1. Adults
with HIV
with
neuropathic
pain
refractory to
at least two
previous
analgesics
1. Adults
with HIV
infection and
chronic pain
2. Had a
stable
medication
regimen

Exclusion
Criteria
1. Unstable
Health
2. Substance
abuser
3. Psychiatric
disorder
4. Current MS
exacerbations
including positive
Lhermitte’s sign
1. Unstable
Health
2. Substance
abuser
3. Psychiatric
disorder
4. Positive urine
toxicology screen
1. Unstable
Health
2. Substance
abuser or smoker
3. Have never
had prior
experience
smoking cannabis

W/D

Interventions

2

Oromuscosal
Cannabis
Spray vs.
Oromuscosal
Placebo Spray

6

Smoked
Cannabis vs.
Placebo

5

Smoked
Cannabis vs.
Placebo
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OUTCOMES MEASURED
In the study by Rog et al, outcomes were measured daily using an 11-point numerical
scale, with 0 being no pain and 10 being the worst possible pain. Every day, participants were
randomly assigned either an oromucosal spray containing plant derived cannabis-based medicine
THC:CBD or a placebo that contained compounds to mimic the appearance, taste and smell of
the THC:CBD spray with no active components. Participants were blinded to whether they
received the cannabis or the placebo. After a 7 day baseline period, daily results were recorded
over the course of 4 weeks.1
In the study by Ellis et al, outcomes were measured by a Descriptor Differential Scale
(DDS). The DDS is a ratio scale containing 24 words describing pain intensity. Ratings are
averaged to provide a summary score on a 0- to 20- point scale. Members participated in a 5
phase study over the course of 7 weeks. Phase 1 lasted one week and was meant to secure a
baseline. During Phase 2 and 4, participants were blindly and randomly given either a placebo or
cannabis to smoke under the observation of a study nurse four times a day for 5 days. During
Phase 3 and 5, participants weren’t given any cannabis or placebo to achieve a “wash-out” period
and allow for the cleansing of cannabis from their system while also observing secondary affects.
These two phases lasted two weeks each. The effects were recorded using the DDS. 2
In the study by Abrams et al, outcomes were measured with a self-reported visual analog
scale from 0- to 100-points, with 0 being no pain and 100 being the worst amount of pain, and
recorded in a daily diary. Members participated in a 4 phase study: Phase 1 was a preintervention phase; Phase 2 was an acclimation phase; Phase 3 was the intervention phase; and
Phase 4 was the post-intervention phase. Baseline measurements were obtained during Phase 2.
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During phase 3, participants were blindly and randomly given either a placebo or a cannabis
cigarette under supervision. Data measurements were collected throughout all 4 phases.3
RESULTS
Three double blind, randomized placebo-controlled trials were used to compare whether
medical cannabis vs placebo offered a decrease in pain intensity in patients with chronic
neuropathic pain caused by systemic diseases such as HIV and MS.
Significant mean reductions favoring CBM were found for the primary outcome of pain
in HIV patients as reported by Rog et al. Of the total 65 patients, 59 (89%) had dysesthetic pain
and seven (11%) had painful spasms. In the patients with dysesthetic pain, the mean change in
pain was -2.4 (SD = 1.5, n = 30) for CBM and -1.3 (SD = 1.7, n = 28) for placebo. In patients
with spasm, the mean changes were -5.7 (SD = 3.5, n = 3) and -2.1 (SD = 1.6, n=4). 30% of
CBM participants experienced at least one adverse event compared to the 22% of placebo
participants. These adverse events included dizziness, dry mouth, weakness, fatigue, etc. No
adverse events were serious; however two female patients had to be removed from the trial due
to the severity of their adverse event. Table 2 breaks down the control event rate, experimental
event rate, relative and absolute risk ratios, and the numbers needed to treat. 1

Table 2: Analysis data comparing CBM and placebo use in patients with chronic
neuropathic pain using an 11-point sliding scale reported by Rog et al
Rog

Patients

CER

EER

RRR

ARR

NNT

64

.24

.52

1.17

.28

4
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In the trial conducted by Ellis et al, pain reduction was significantly greater with cannabis
compared to placebo (median difference in pain reduction =3.3 DDS points). The active cannabis
group achieved pain reduction of 30% greater than the placebo cannabis week (0.46 (95%CI
0.28, 0.65) vs 0.18 (0.03, 0.32), p=0.043). The number needed to treat (NNT) to achieve 30%
pain reduction was 3.5 (95% CI 1.9, 20.8). Also, the median change in pain scores from baseline
was -17 (-58, 52) for cannabis as compared to -4 (-56, 28) for placebo (p=0.001). Adverse events
were noted in the smoked cannabis group more-so than in the placebo group, but like the trial by
Rog et al, they were mild and not serious. Table 3 breaks down the control event rate,
experimental event rate, relative and absolute risk ratios, and the numbers needed to treat.2

Table 3: Analysis data comparing CBM and placebo use in patients with chronic
neuropathic pain using the descriptor differential scale reported by Ellis et al
Ellis

Patients

CER

EER

RRR

ARR

NNT

26

.18

.46

1.56

.28

4

In the trial conducted by Abrams et al, 13 of 25 patients who were given cannabis
cigarettes had >30% reduction in pain from baseline to end of treatment as opposed to 6 of 25
patients receiving placebo cigarettes (52% vs 24%; difference of 28%, 95% CI 2% to 54%, p =
0.04). The median reduction in chronic neuropathic pain on the daily diary visual analog scale
was 34% in the cannabis group and 17% in the placebo group; difference = 18%; p = 0.03.
Adverse events were similar to the trails by Rog et al and Ellis et al, however no participants
withdrew from the study due to them. Table 4 breaks down the data depicting baseline daily
visual analog scale scores in both study groups as well as the average daily scores during the
treatment phase.3
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Table 4: Analysis data comparing CBM and placebo use in patients with chronic
neuropathic pain using a daily diary of self-reported visual analog scale scores reported by
Abrams et al
Abrams

Intervention

Patients

CBM

25

Placebo

25

Baseline Score
6.58 (6.007.15)
6.37 (5.776.97)

Final
Treatment
3.85 (3.134.58)
4.96 (4.195.72)

Mean
Difference
-1.25
(-2.11
to -0.39)
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DISCUSSION
In assessing the three randomized controlled trials comparing cannabis-based medicine to
placebo in reducing chronic neuropathic pain, it’s important to note the limitations of the studies.
Complications arising from the use of CBM were minimal, with acute adverse events ranging
from mild dizziness, nausea, weakness, dry mouth, and fatigue being few and far between with
little impact on the overall outcome. Only 2 of the 65 participants in the Rog trial removed
themselves from the study due to the adverse events, making them the only participants that were
removed due to the effects of CBM from all three trials. However, the more notable side effects
from chronic use of cannabis arise more in the long-term, making these complications appear
less impactful than they really are. As an example, in an article published by The Journal of the
American Medical Association, heavy chronic marijuana use is “associated with residual
neurophysiological effects even after day of supervised abstinence”. 6
Also, while the aim of these trials were to demonstrate whether alternative therapy for
chronic neuropathic pain existed for those who can’t tolerate or are refractory to traditional
therapy, there was no comparison made in the decrease in pain intensity between CBM and
traditional therapy. Without knowing how CBM compares to opioids, NSAID’s, and
anticonvulsants, it is unclear whether CBM is the superior form of chronic pain management.
Because of this, while CBM does decrease the intensity of chronic neuropathic pain, there is no
evidence to suggest that it should be the primary form of pain management. Likewise, it would
also be appropriate to determine whether CBM would be a suitable adjunctive therapy with
traditional therapy to further decrease the pain intensity.
Probably the most important issue with the use of CBM for chronic pain is the legal
ramifications of its use. While 23 states have legalized the use of CBM, marijuana is still a
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category 1 drug as mandated by the DEA and it’s still illegal according to federal law. So long as
you’re in a state that has a law which contradicts a federal law, you are protected by that state
and in most cases will not be interfered with by the federal authorities. However, until CBM is
downgraded in the DEA category list and is no longer illegal under federal law, the FDA will
never approve its use for chronic neuropathic pain, which is just another pain these patients have
to deal with.

CONCLUSION
The results from the three randomized controlled trials comparing oral or inhaled
cannabis-based medicine (CBM) to placebo in decreasing the intensity of chronic neuropathic
pain in chronic diseases such as HIV and MS reveals that there is a significant decrease in pain in
those taking the CBM. For those individuals who are unable to take traditional therapy due to
their side effects or ineffectiveness, CBM appears to be a suitable replacement to aid in the day
to day lives of people with these debilitating disorders. As the individual states continue to
legalize medicinal marijuana, the scope of its use will further broaden; making trials such as the
three depicted in this review an important resource to guide future studies.
An interesting question that wasn’t addressed in any of the three trials was whether CBM
or homegrown marijuana displayed any changes to the outcomes of pain management. With any
medical treatment, controlling the dosing is one of the most important variables. With purchased
marijuana, depending on the provider the THC content can fluctuate, making no two marijuana
cigarettes between different providers the same. This poses a problem for homegrown marijuana
in the treatment of chronic pain because if the treatment is failing or serious side effects begin to
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show there is no way to determine if the issues are being caused by the marijuana or by the
dosing. However, should a provider instead give the means to grow their marijuana from the
same germ line, then in theory the THC content should be equal amongst each marijuana
cigarette should each cigarette contain the same amount of leaf content. It is important to
consider homegrown marijuana as opposed to pharmacy administered marijuana, because if
homegrown marijuana can be monitored and managed appropriately, it would cut down on the
expenses to both the patient and the healthcare system dramatically, which would further aid to
the credibility of CBM use for chronic neuropathic pain.
Acknowledging that the short-term side effects of CBM were minimal and lacking any
serious impact on these trials is important, however the long-term effects of chronic use of CBM
were never entertained and needs to be investigated further. While the question was successfully
answered in regards to whether CBM can significantly decrease the intensity of chronic
neuropathic pain, before a final conclusion can be made regarding CBM’s placement in the
hierarchy of the treatment plan, more research needs to be conducted.
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